

## SEQUENT SCIENTIFIC LIMITED

### UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2010

(₹ in Million)

Particulars	STANDALONE				
	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED
	31-12-2010 Unaudited	31-12-2009 Unaudited	31-12-2010 Unaudited	31-12-2009 Unaudited	31-03-2010 Audited
1 Net Sales / Income from Operations	529.79	647.31	1,865.31	1,922.56	2,463.35
Other Operating Income	150.00	-	150.00	-	-
<b>Total Revenue</b>	<b>679.79</b>	<b>647.31</b>	<b>2,015.31</b>	<b>1,922.56</b>	<b>2,463.35</b>
2 <b>Expenditure</b>					
a) (Increase)/Decrease in stock in trade and work in progress	(22.42)	(32.67)	(139.43)	(75.89)	(75.76)
b) Consumption of Raw Materials	277.76	316.53	840.58	816.56	1,081.53
c) Purchase of Traded Goods	32.15	7.28	289.23	27.49	31.60
d) Conversion charges	34.04	22.56	84.48	69.46	99.62
e) Employee Cost	65.32	56.23	186.51	163.38	202.05
f) Depreciation	41.50	32.33	122.14	93.04	125.22
g) Other Expenditure	157.20	158.49	402.95	414.06	523.45
Total	585.55	560.75	1,786.46	1,508.10	1,987.71
3 <b>Profit/(Loss) from Operations before other income, interest and exceptional items.</b>	<b>94.24</b>	<b>86.56</b>	<b>228.85</b>	<b>414.46</b>	<b>475.64</b>
4 Other Income	10.62	10.22	49.67	21.85	72.87
5 <b>Profit/(Loss) before interest &amp; exceptional Items</b>	<b>104.86</b>	<b>96.78</b>	<b>278.52</b>	<b>436.31</b>	<b>548.51</b>
6 Financial cost	56.71	46.32	145.07	142.72	187.32
7 <b>Profit/(Loss) after interest but before exceptional Items</b>	<b>48.15</b>	<b>50.46</b>	<b>133.45</b>	<b>293.59</b>	<b>361.19</b>
8 Exceptional items	-	5.39	(52.48)	33.96	57.50
9 <b>Profit/(Loss) from ordinary activity before tax</b>	<b>48.15</b>	<b>45.07</b>	<b>185.93</b>	<b>259.63</b>	<b>303.69</b>
10 Tax Expense	7.83	9.80	33.73	70.64	95.76
11 <b>Net Profit/(Loss) from Ordinary activities after tax</b>	<b>40.32</b>	<b>35.27</b>	<b>152.20</b>	<b>188.99</b>	<b>207.93</b>
12 Extraordinary items	-	-	-	-	-
13 <b>Net Profit</b>	<b>40.32</b>	<b>35.27</b>	<b>152.20</b>	<b>188.99</b>	<b>207.93</b>
14 Paid-up equity share capital (Face Value per share ₹ 10/each)	219.35	212.35	219.35	212.35	212.35
15 Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year					946.29
16 Earnings Per Share before Extraordinary Items for the period (Non-Annualised)					
Basic (₹)	1.84	1.66	6.94	8.90	9.79
Diluted (₹)	1.84	1.66	6.94	8.90	9.79
Earnings Per Share after Extraordinary Items for the period (Non-Annualised)					
Basic (₹)	1.84	1.66	6.94	8.90	9.79
Diluted (₹)	1.84	1.66	6.94	8.90	9.79
17 Public Share Holding					
No. of Shares	6,322,255	6,210,553	6,322,255	6,210,553	6,185,553
% of Share Holding	28.82%	29.25%	28.82%	29.25%	29.13%
18 Promoters and Promoter Group Shareholding					
a) Pledged / Encumbered					
1. No of shares	2,300,000	Nil	2,300,000	Nil	Nil
2. Percentage of shares(as a % of the total shareholding of promoter & promoter group)	14.73%	NA	14.73%	NA	NA
3. Percentage of shares (as a % of the total share capital of the company)	10.49%	NA	10.49%	NA	NA
b) Non-encumbered					
1. No of shares	13,312,936	15,024,638	13,312,936	15,024,638	15,049,638
2. Percentage of shares(as a % of the total shareholding of promoter & promoter group)	85.27%	100%	85.27%	100%	100%
3. Percentage of shares (as a % of the total share capital of the company)	60.69%	70.75%	60.69%	70.75%	70.87%

#### Notes

- The unaudited financial results were taken on record by the Board of Directors at its meeting held on February 10, 2011.
- The statutory auditors have performed a limited review of the standalone financial results for the period ended as on December 31, 2010 of the Company as required by the Clause 41 of the Listing Agreement.
- The Company is in the process of filing an application to the Central Government for seeking approval for payment of Managerial Remuneration exceeding the limits specified in the Schedule XIII of the Companies Act, 1956.
- The Scheme of amalgamation of Vedic Elements Private Limited ("Transferor Company") with the Company ("Transferee Company") with an appointed date of October 1, 2009 ("The Scheme"), has been sanctioned by the High Court of Karnataka and came into effect on 07 September 2010. In terms of the Scheme:
  - The assets and liabilities of the Transferor Company have been recorded in the books based on values determined by the Board of Directors of the Transferee Company.
  - The reserves and balances in profit and loss account of the Transferor Company has been recorded in the same form and at same values as they appear in the financial statements of the Transferor Company as on the appointed date.
  - The carrying value of investments in the shares of the Transferor Company held by the Transferee Company and inter-corporate balances stand cancelled.
  - Upon the scheme becoming effective, the assets and liabilities of the Transferee Company have been revalued based on valuation report or value determined by the Board of Directors of the Company and the net surplus of ₹ 340.05 Million arising out of such valuations (over the carrying value of the respective assets and liabilities prior to the valuation) have been credited to the Restructuring Reserve account.
  - The deficit arising on amalgamation of ₹ 337.02 Million representing the value of assets over the value of liabilities of the Transferor Company, after cancellation of capital of the transferor Company and the reserves recorded as per point 'B', has been set-off against Restructuring reserve account as created in point 'd' above post merger.
  - Had the Scheme not provided for valuing the assets and liabilities of the Transferee Company, the effect of accounting as per the Accounting standards issued under the Companies (Accounting Standards) Rules, 2006 for the

current quarter and for the nine months ended December 31, 2010, would have been as under:

- Depreciation expenses for the quarter and Nine month ended would have been lower by ₹ 2.04 Million and ₹ 6.12 Million respectively, decrease in income from exceptional item for the nine month ended lower by ₹ 57.50 Million. The resultant impact on profit after tax for the quarter and Nine month ended December 31, 2010 being higher by ₹ 2.04 Million and lower by ₹ 86.16 Million respectively.
- Earning Per Share (EPS) (Face Value of ₹10/-each) (₹)

	Quarter Ended 31-Dec-10	Nine Months ended 31-Dec-10
Basic	1.93	3.01
Diluted	1.93	3.01

- Details of investor complaints for the quarter ended 31st December 2010:
 

Unresolved at the beginning of the quarter :	Nil
Received during the quarter :	Nil
Disposed off during the quarter :	Nil
Unresolved at the end of quarter :	Nil
- During the quarter the company's wholly owned subsidiary SeQuent Penems Private limited made preferential allotment of shares to SeQuent Speciality Chemicals Private Limited resulting in SeQuent Penems Private Limited becoming an associate from a subsidiary.
- During the period the Company has decided to merge its holding company, Fraxis Life Sciences Private Limited. The Company is in the process of obtaining necessary approvals.
- Segment Results
 

The company has identified Pharmaceuticals and Speciality Chemicals as its business segments, Segments have been identified taking in to account the nature of products, the differing risks & returns, the organisational structure & the internal reporting system.

#### Segment wise Revenue, Results and Capital Employed:

Segment wise Revenue, Results and Capital Employed					(₹ in Million)
Particulars	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED
	31-12-2010 Unaudited	31-12-2009 Unaudited	31-12-2010 Unaudited	31-12-2009 Unaudited	31-03-2010 Audited
1 <b>Segment Revenue</b>					
a) Pharmaceuticals	573.96	565.34	1,712.86	1,570.82	1,915.54
b) Speciality Chemicals	153.44	116.97	379.62	393.21	596.14
<b>Total</b>	<b>727.40</b>	<b>682.31</b>	<b>2,092.48</b>	<b>1,964.03</b>	<b>2,511.68</b>
Less Intersegment Revenue	47.61	35.00	77.17	41.47	48.33
Add other unallocated Income					
<b>Net Sales /Income from Operations</b>	<b>679.79</b>	<b>647.31</b>	<b>2,015.31</b>	<b>1,922.56</b>	<b>2,463.35</b>
2 <b>Segment Results</b>					
<b>Profit or Loss before Tax and Interest from Each Segment</b>					
a) Pharmaceuticals	86.73	105.91	233.06	450.43	378.19
b) Speciality Chemicals	32.53	44.09	92.20	139.27	197.02
<b>Total</b>	<b>119.26</b>	<b>150.00</b>	<b>325.26</b>	<b>589.70</b>	<b>575.21</b>
Less (i) Finance Cost	56.72	46.32	145.07	142.72	187.31
(ii) other unallocable expenditure net off unallocable income	14.39	58.61	(5.74)	187.35	84.21
Total Profit Before Tax	48.15	45.07	185.93	259.63	303.69
3 Capital Employed					
a) Pharmaceuticals	4,201.80	1,382.78	4,201.80	1,382.78	2,974.29
b) Speciality Chemicals	345.97	334.20	345.97	334.20	329.07
c) Unallocated	(1,277.34)	846.59	(1,277.34)	846.59	(690.11)
<b>Total</b>	<b>3,270.43</b>	<b>2,563.57</b>	<b>3,270.43</b>	<b>2,563.57</b>	<b>2,613.25</b>

9. Figures for previous periods may have been regrouped and rearranged, wherever necessary, to confirm to the relevant current period classification.

Place : Bengaluru  
Date : February 10, 2011

For and on behalf of the Board  
**K. R. RAVISHANKAR**  
Chairman & Managing Director

Corporate Office: Star II, Opp. IIM, Bilekahalli, Bannerghatta Road, Bangalore-560 076. India. Tel.: +91-80-66580340 Fax: +91-80-66580400  
Regd. Office : 116, Vardhaman Industrial Complex, L B S Marg, Thane (W), Mumbai - 400 601, India. Tel.: +91-22-21721355, 21723357 Fax: +91-22-21721111

18x43

10th feb 2010